Login
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc.

emergentbiosolutions.com

What Do They Do?

Sells vaccines and treatments for public-health threats to government customers, and naloxone nasal sprays to pharmacies, public agencies and community groups.

How Do They Make Money?

Government buyers purchase MCM products through contracts, with sales tied to delivery and customer acceptance; pharmacies and wholesalers receive naloxone products. Bioservices customers pay as manufacturing and development work progresses, while reserved capacity is paid over time; contracts and grants also contribute.

revenue
SegmentShareRevenue
Commercial Product sales
Sold outright

30%
FY2022: 35%
MCM Product sales
Sold outright

61%
FY2022: 52%
All other revenues
8.1%

Who Are Their Customers?

U.S. and other governments buy MCM products; naloxone is sold through pharmacies and online, and through prescriptions or standing orders to public agencies and community groups. Bioservices serve government agencies, pharmaceutical companies and nonprofits.

Customers above 10% of revenue, FY2025
of revenue from one customer
FY2023: 38% from one customer

Do Revenues Turn Into Profits?

Yes. It kept 7 cents of every revenue dollar as net income in FY2025 and turned 21 cents into free cash flow.

Operating income, FY2025
13% of revenue
▲ Turned profitable vs FY2024 (−$108.7M, −10%)
Net income, FY2025
7% of revenue
▲ Turned profitable vs FY2024 (−$190.6M, −18%)
Free cash flow, FY2025
21% of revenue
▲ +338% vs FY2024 ($35.8M, 3%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −52%
vs $231.1M in Q3 FY2025
Net income
▼ Turned to a loss
vs $51.2M in Q3 FY2025
MCM Product sales share of revenue vs 61.7% in Q3 FY2025
  • Apr 30, 2026 Agrees to future U.S. distribution rights for a Japanese encephalitis vaccine The Substipharm partnership includes manufacturing and U.S. distribution rights after FDA approval.

Shrinking. Revenue fell 58% in 4 years, from $1.8B in FY2021 to $742.9M in FY2025, about 20% a year.

Travel health divestiture The older report included travelers’ vaccines sold through travel clinics, pharmacies and vaccination centers. The latest report focuses the commercial business on naloxone sprays and says the travel-health business was sold.

Reduced services focus The older report described development and manufacturing services for biotechnology and pharmaceutical innovators. The latest report says it reduced investment in and de-emphasized Services after facility closures and sales.

Revenue over time
Commercial Product sales MCM Product sales All other revenues Contracts and grants Services Total Product sales, net
$2B$1B$0

Who Do They Compete With?

Competes with KM Biologics, GC Biopharma, Blue Willow Biologics, Greffex, SIGA, Teva Pharmaceuticals Industries, Padagis Pharmaceuticals, Amneal Pharmaceuticals, Amphastar Pharmaceuticals, Adamis, Harm Reduction Therapeutics, Indivior, Summit Biosciences, Elusys Therapeutics, Thermo Fisher Scientific, Lonza, FUJIFILM Biotechnologies, Grand River Aseptic Manufacturing, Pyramid Bioservices, and PCI

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support